## Ropivacaine Hydrochloride Injection, USP $10 \mathrm{mg} / \mathrm{mL}$ Ampoule 20 mL Backorder Notice

Dear Valued Customer,
Fresenius Kabi Canada regrets to advise that due to a production delay, we will be facing a supply interruption on our Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL effective February 1, 2023 until April 30, 2023.

| DIN | Fresenius <br> Kabi <br> Product <br> Code | MDP <br> Product <br> Code | McKesson <br> Product <br> Code | Product Description | Estimated <br> Stockout Date* | Estimated <br> Availability Date |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 02439409 | ABA1847 | 974882 | 124915 | Ropivacaine Hydrochloride <br> Injection, USP $10 \mathrm{mg} / \mathrm{mL}$ <br> Ampoule 20 mL | Feb. 1, 2023 | Apr. 30, 2023 |

*Please note that the stockout date may vary by region, please check your local distribution centre for availability.
During this time, allocations for our Ropivacaine Hydrochloride Injection, USP 10 mg/mL
Ampoule 10 mL will be increased. Contract customers will be allocated $100 \%$ of historical 10 mL demand plus $\mathbf{1 0 0 \%}$ of $\mathbf{2 0 ~ m L}$ demand at a 2:1 ratio ( 2 vials of $10 \mathrm{~mL}=1$ vial of 20 mL ).

| DIN | Fresenius <br> Kabi Product <br> Code | MDP <br> Product <br> Code | McKesson <br> Product <br> Code | Product Description | Allocation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 02439409 | ABA1846 | 974894 | 124903 | Ropivacaine Hydrochloride Injection, <br> USP $10 \mathrm{mg} / \mathrm{mL}$ Ampoule 10 mL | Effective Feb. 1, 2023, <br> allocations will be increased <br> to cover $100 \%$ of 10 mL <br> demand plus $100 \%$ of <br> 20 mL demand at a 2:1 ratio. |

We recognize the difficulties and inconvenience that you may encounter as a result of our supply interruption, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

[^0]
[^0]:    George Shamsoun
    Director of Marketing, Generics and Nutrition
    george.shamsoun@fresenius-kabi.com

